التفاصيل البيبلوغرافية
| العنوان: |
Test me now or, test me later: prospective study of molecular testing in ovarian cancer. |
| المؤلفون: |
Scalise, Matthew1 (AUTHOR), Foxall, McKenzie1 (AUTHOR), Thigpen, Haley1 (AUTHOR), Scalise, Carly Bess1 (AUTHOR), Arend, Rebecca1 (AUTHOR) |
| المصدر: |
Gynecologic Oncology. 2021 Supplement 1, Vol. 162, pS287-S287. 1p. |
| مصطلحات موضوعية: |
*OVARIAN cancer, *LONGITUDINAL method, *TURNAROUND time, *CANCER patients, *NUCLEOTIDE sequencing, *INDIVIDUALIZED medicine |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
Advances in molecular tumor profiling through Next-Generation Sequencing (NGS) has led to an increase in available therapeutic options for patients with gynecologic malignancies beyond standard chemotherapy. Specifically, the addition of Poly-(ADP-ribose) Polymerase inhibitors (PARPi) has signaled a paradigm shift in the management of ovarian cancer. The objective of this prospective study was to evaluate how the timing of NGS has affected the implementation of PARPi within a patient's treatment timeline between 2016 and 2019 at a single institution. Ovarian cancer patients were enrolled in a prospective Personalized Medicine Initiative (PMI) from January 2016 to December 2019 at a single institution. Archival tissue from each patient was sent for NGS testing. Initially, the project included only patients with recurrent or progressive ovarian cancer. This was expanded in a stepwise fashion to now include newly diagnosed high-grade, advanced stage ovarian cancer patients. Primarily, descriptive statistics were used to analyze the data. Of the 308 patients, 251 (81%) had stage III or IV disease; 216 (70%) had high grade serous histology. NGS successfully identified 197 (64%) patients with at least one genetic alteration directed towards an FDA-approved or standard of care therapy. 27 (39%) received a PARPi due to wt BRCA , 25 (36%) for s BRCA, 8 (11%) for g BRCA , and 6 (8%) for LOH+/BRCAwt. The average time between initial diagnosis and NGS decreased from approximately 46 months in 2016-2017 to 30 months in 2018-2019. Likewise, the average number of lines of therapy completed before NGS decreased from 3 in 2016-2017 to 1 in 2018-2019. Furthermore, we found that the time between NGS and PARPi implementation decreased from an average of 12 to 5 months from 2016 to 2019, respectively. Increasingly, early implementation of NGS in the management of ovarian cancers has allowed for more patients to be placed on targeted therapies, including PARPi, for which they otherwise would not be eligible. After 2019, the majority of patients received NGS prior to their second line of treatment. This data suggests early NGS permits PARPi to be used at an earlier time point within a patient's treatment course. Currently, we are testing all newly diagnosed high-grade, advanced stage ovarian cancer patients at as soon as tissue is available to help guide further treatment decisions. In addition, this study demonstrates NGS has a clinically compatible turnaround time, which may guide clinical management of patients with ovarian cancer. Further follow-up studies need to evaluate the impact of earlier PARPi implementation on patient survival. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
